Patents by Inventor Robert Heald
Robert Heald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230242503Abstract: The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.Type: ApplicationFiled: August 9, 2019Publication date: August 3, 2023Applicant: Artios Pharma LimitedInventors: Peter BLENCOWE, Mark CHARLES, Tennyson EKWURU, Harry FINCH, Robert HEALD, Hollie MCCARRON, Martin STOCKLEY
-
Publication number: 20220298134Abstract: The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.Type: ApplicationFiled: August 9, 2019Publication date: September 22, 2022Applicant: Artios Pharma LimitedInventors: Peter BLENCOWE, Mark CHARLES, Tennyson EKWURU, Harry FINCH, Robert HEALD, Hollie MCCARRON, Martin STOCKLEY
-
Publication number: 20220259174Abstract: The application relates to deuterated amide derivatives of formula (I) and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.Type: ApplicationFiled: August 10, 2020Publication date: August 18, 2022Applicant: Artios Pharma LimitedInventors: Peter BLENCOWE, Mark CHARLES, Tennyson EKWURU, Harry FINCH, Hollie MCCARRON, Robert HEALD, Martin STOCKLEY
-
Patent number: 10709579Abstract: The present disclosure provides a device and method for applying a bone graft material to the body. The device includes a cylinder into which bone graft material is loaded. Specifically, the bone graft material is loaded into the cylinder through a funnel at a proximal end of the cylinder and dispensed through a tip at a distal end of the cylinder. After the bone graft material is loaded, a sleeve within the cylinder can be removed in order to create a channel within the bone graft material. Water or other hydrating fluid may be inserted into the channel through a port adjacent the proximal end of the cylinder in order to hydrate the bone graft material.Type: GrantFiled: September 26, 2018Date of Patent: July 14, 2020Inventors: Robert Heald, Richard Lim
-
Patent number: 10271962Abstract: The present disclosure provides a device and method for applying a bone graft material to the body. The device includes a cylinder into which bone graft material is loaded. Specifically, the bone graft material is loaded into the cylinder through a funnel at a proximal end of the cylinder and dispensed through a tip at a distal end of the cylinder. After the bone graft material is loaded, a sleeve within the cylinder can be removed in order to create a channel within the bone graft material. Water or other hydrating fluid may be inserted into the channel through a port adjacent the proximal end of the cylinder in order to hydrate the bone graft material.Type: GrantFiled: November 13, 2017Date of Patent: April 30, 2019Inventors: Robert Heald, Richard Lim
-
Publication number: 20190021878Abstract: The present disclosure provides a device and method for applying a bone graft material to the body. The device includes a cylinder into which bone graft material is loaded. Specifically, the bone graft material is loaded into the cylinder through a funnel at a proximal end of the cylinder and dispensed through a tip at a distal end of the cylinder. After the bone graft material is loaded, a sleeve within the cylinder can be removed in order to create a channel within the bone graft material. Water or other hydrating fluid may be inserted into the channel through a port adjacent the proximal end of the cylinder in order to hydrate the bone graft material.Type: ApplicationFiled: September 26, 2018Publication date: January 24, 2019Inventors: Robert Heald, Richard Lim
-
Publication number: 20180133027Abstract: The present disclosure provides a device and method for applying a bone graft material to the body. The device includes a cylinder into which bone graft material is loaded. Specifically, the bone graft material is loaded into the cylinder through a funnel at a proximal end of the cylinder and dispensed through a tip at a distal end of the cylinder. After the bone graft material is loaded, a sleeve within the cylinder can be removed in order to create a channel within the bone graft material. Water or other hydrating fluid may be inserted into the channel through a port adjacent the proximal end of the cylinder in order to hydrate the bone graft material.Type: ApplicationFiled: November 13, 2017Publication date: May 17, 2018Inventors: Robert Heald, Richard Lim
-
Patent number: 9951064Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.Type: GrantFiled: May 12, 2016Date of Patent: April 24, 2018Assignee: GENENTECH, INC.Inventors: Marian C. Bryan, Bryan Chan, Francois Diederich, Jennafer Dotson, Emily Hanan, Timothy Heffron, Michael Lainchbury, Robert Heald, Eileen M. Seward
-
Patent number: 9890152Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.Type: GrantFiled: June 19, 2015Date of Patent: February 13, 2018Assignee: GENENTECH, INC.Inventors: Marian C. Bryan, Bryan Chan, Emily Hanan, Timothy Heffron, Hans Purkey, Richard Leonard Elliott, Robert Heald, Jamie Knight, Michael Lainchbury, Eileen M. Seward
-
Patent number: 9670228Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: December 5, 2016Date of Patent: June 6, 2017Assignee: Genentech, Inc.Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
-
Publication number: 20170081341Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: December 5, 2016Publication date: March 23, 2017Applicant: Genentech, Inc.Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
-
Patent number: 9546178Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: November 3, 2015Date of Patent: January 17, 2017Assignee: Genentech, Inc.Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
-
Publication number: 20160052933Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: November 3, 2015Publication date: February 25, 2016Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
-
Publication number: 20160016948Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.Type: ApplicationFiled: June 19, 2015Publication date: January 21, 2016Applicant: GENENTECH, INC.Inventors: Marian C. Bryan, Bryan Chan, Emily Hanan, Timothy Heffron, Hans Purkey, Richard Leonard Elliott, Robert Heald, Jamie Knight, Michael Lainchbury, Eileen M. Seward
-
Patent number: 9206174Abstract: The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity.Type: GrantFiled: February 5, 2013Date of Patent: December 8, 2015Assignee: Genentech, Inc.Inventor: Robert Heald
-
Patent number: 9198918Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: June 5, 2014Date of Patent: December 1, 2015Assignee: GENENTECH, INC.Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
-
Patent number: 9175009Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: December 10, 2014Date of Patent: November 3, 2015Assignee: GENENTECH, INC.Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Richard Goldsmith, Robert Heald, Timothy Heffron, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, BinQing Wei
-
Patent number: 9090628Abstract: Benzoxazepin Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: March 20, 2012Date of Patent: July 28, 2015Assignee: GENENTECH, INC.Inventors: Timothy Heffron, Brian Safina, Steven Staben, Daniel P. Sutherlin, BinQing Wei, Richard Elliott, Robert Heald, Eileen M. Seward, Emanuela Gancia, Bohdan Waszkowycz
-
Publication number: 20150094347Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Richard Goldsmith, Robert Heald, Timothy Heffron, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, BinQing Wei
-
Patent number: 8952043Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: January 23, 2014Date of Patent: February 10, 2015Assignee: Genetech, Inc.Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Richard Goldsmith, Robert Heald, Timothy Heffron, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, BinQing Wei